Weiner, Sophia
Junkkari, Antti
Sauer, Mathias
Luikku, Antti
Rauramaa, Tuomas
Kokkola, Tarja
Herukka, Sanna-Kaisa
Blennow, Kaj
Zetterberg, Henrik
Leinonen, Ville
Gobom, Johan
Funding for this research was provided by:
Stiftelsen för Gamla Tjänarinnor
Swedish Research Council (#2017-00915, #2018-02532)
Alzheimer's Drug Discovery Foundation (#RDAPB-201809-2016615, #201809-2016862)
Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270)
Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006)
ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
National Institutes of Health (#1R01AG068398-01)
Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495)
European Union’s Horizon Europe research and innovation programme (101053962)
Swedish State Support for Clinical Research (#ALFGBG-71320)
AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C)
Bluefield Project
Olav Thon Foundation
Erling-Persson Family Foundation
Hjärnfonden (#FO2022-0270)
Marie Skłodowska-Curie grant (860197)
European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute (UKDRI-1003)
Alzheimerfonden (AF-980746)
Stiftelsen Gamla tjänarinnor (2022-01324)
University of Gothenburg
Article History
Received: 7 March 2023
Accepted: 9 May 2023
First Online: 5 June 2023
Declarations
:
: The study was conducted according to the Declaration of Helsinki and all patients provided informed consent. The Research Ethics Committee of the Northern Savo Hospital District (decision No 276/13.02.00/2016).
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors report no disclosures.